文献速递肿瘤 PET/CT神经核医学

18F-DOPA PET/CT在小肠神经内分泌肿瘤初始或术前评估中的前沿作用

18F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2022-05-19

这项回顾性多中心非干预研究比较了68Ga-DOTATOC与18F-DOPA PET/CT在小肠神经内分泌肿瘤初始分期或术前评估中的价值,纳入53例未手术患者。18F-DOPA PET/CT检测到更多病灶,包括肠系膜淋巴结及肝、腹膜、肺转移,但两者对原发肿瘤检出率相同。

要点

  • 18F-DOPA PET/CT在53例小肠神经内分泌肿瘤患者中检测到的病灶数多于68Ga-DOTATOC PET/CT。
  • 两者对原发肿瘤的检出率相同,均为92%(34/37)。
  • 18F-DOPA PET/CT检测到更多肝、腹膜和肺转移(均P<0.001)。

核心结论

  • 在所研究患者中,18F-DOPA PET/CT检测到的病灶数多于68Ga-DOTATOC PET/CT。
  • 两种检查在小肠神经内分泌肿瘤分期和治疗选择中的各自作用应予以讨论。

研究设计与样本

  • 回顾性、多中心、非干预性研究,纳入53例未手术治疗的小肠神经内分泌肿瘤患者。
  • 患者均在6个月间隔内接受68Ga-DOTATOC和18F-DOPA PET/CT检查,两次检查之间无手术干预或治疗改变。
  • 原发肿瘤检出敏感性在37例手术治疗患者中评估,以手术结果(76个小肠神经内分泌肿瘤)为诊断金标准。

主要发现

  • 68Ga-DOTATOC和18F-DOPA PET/CT各自在92%(34/37)的患者中至少识别出1个原发小肠神经内分泌肿瘤。
  • 组织学证实8例患者存在肠道肿瘤多灶性;两种检查对多灶性一致阳性5例、不一致阳性2例、一致阴性1例。
  • 基于区域分析,膈下淋巴结转移检出率分别为68Ga-DOTATOC 91%和18F-DOPA PET/CT 98%(P=0.18),18F-DOPA PET/CT检测到更多异常膈下淋巴结(P=0.009)。
  • 仅针对肠系膜淋巴结,18F-DOPA PET/CT检测到更多阳性区域(P=0.005)和淋巴结病灶(P=0.003),包括肠系膜血管起始部的淋巴结。
  • 对于远处转移的检出,两种检查基于区域分析表现相当;与68Ga-DOTATOC相比,18F-DOPA PET/CT检测到更多肝转移(P<0.001)、腹膜转移(P<0.001)和肺转移(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to compare the respective value of 68Ga-DOTATOC and 18F-DOPA PET/CT for initial staging or presurgical work-up of patients with small-intestine neuroendocrine tumors (SiNETs). Methods: This was a retrospective, multicenter, noninterventional investigation involving 53 non-surgically treated SiNET patients who underwent both 68Ga-DOTATOC and 18F-DOPA PET/CT within a 6-mo interval without surgical intervention or therapeutic change between the 2 PET/CT studies. Percentage detection rate was calculated according to per-region and per-lesion analyses. Sensitivity for primary tumor detection was assessed in 37 surgically treated patients, taking surgical results (76 SiNETs) as the diagnostic gold standard. Results: 68Ga-DOTATOC PET/CT and 18F-DOPA PET/CT individually identified at least 1 primary SiNET in 92% (34/37) of the patients. Intestinal tumor multifocality was confirmed by histology in 8 patients. 68Ga-DOTATOC and 18F-DOPA PET/CT were concordantly positive for tumor multifocality in 5 patients, discordantly positive in 2 patients, and concordantly negative in 1 patient. The detection rate for subdiaphragmatic nodal metastases on per-region-based analysis was 91% and 98% for 68Ga-DOTATOC and 18F-DOPA PET/CT, respectively (P = 0.18). 18F-DOPA PET/CT detected a higher number of abnormal subdiaphragmatic nodes (P = 0.009). Regarding mesenteric nodes only, 18F-DOPA PET/CT detected more positive regions (P = 0.005) and nodal lesions (P = 0.003) than 68Ga-DOTATOC PET/CT, including nodes at the origin of mesenteric vessels. For detection of distant metastases, 68Ga-DOTATOC and 18F-DOPA PET/CT performed equally well on a per-region-based analysis. As compared with 68Ga-DOTATOC, 18F-DOPA PET/CT detected more hepatic (P < 0.001), peritoneal (P < 0.001), and lung metastases (P < 0.001). Conclusion: 18F-DOPA PET/CT detected more lesions than 68Ga-DOTATOC PET/CT in the studied patients. The respective roles of the two should be discussed in terms of disease staging and treatment selection.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ouvrard E, Mestier L, Boursier C, et al. 18F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors. J Nucl Med. 2022. PMID: 35589408. doi:10.2967/jnumed.122.263984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。